Currently out of the existing stock ratings of Daina Graybosch, 91 are a BUY (79.82%), 23 are a HOLD (20.18%).

Daina Graybosch

Work Performance Price Targets & Ratings Chart

Analyst Daina Graybosch, currently employed at LEERINK, carries an average stock price target met ratio of 40.59% that have a potential upside of 29.91% achieved within 202 days.

Daina Graybosch’s has documented 199 price targets and ratings displayed on 20 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on IPHA, Innate Pharma at 18-Sep-2025.

Wall Street Analyst Daina Graybosch

Analyst best performing recommendations are on SBTX (SILVERBACK THERAPEUTICS ).
The best stock recommendation documented was for SBTX (SILVERBACK THERAPEUTICS ) at 12/29/2020. The price target of $40 was fulfilled within 1 day with a profit of $3 (8.11%) receiving and performance score of 81.08.

Average potential price target upside

of $27.81 (38.15%) on MRK (MERCK MPANY).
of $25.53 (191.64%) on ACLX (ARCELLX).
of $24.5 (67.89%) on AFMD (AFFIMED NV).

ACLX Arcellx BNTX BioNTech SE FATE Fate Therapeutics MRK Merck mpany SBTX Silverback Therapeutics AFMD Affimed NV CGEN Compugen IPHA Innate Pharma IPSC Century Therapeutics ITOS Iteos Therapeutics MOLN Molecular Partners AG ADR NKTR Nektar Therapeutics BOLT Bolt Biotherapeutics FSTX FStar Therapeutics HOWL Werewolf Therapeutics LVTX LAVA Therapeutics NV TSVT 2Seventy Bio RCUS Arcus Biosciences KDNY Chinook Therapeutics ADRO Aduro Biotech

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

George Farmer (SCOTIABANK)